Current needs and future opportunities

Navigator Medicines is a clinical-stage biopharmaceutical company focused on finding pathways and partnerships that push well beyond the limits of what’s possible in autoimmune disease.

09/17/2025 Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases »

All News

A strong team with a proven track record

Much like medicines, leadership teams should be rigorously tested too. Ours has a history of successfully bringing treatments from early discovery to commercial launch. We understand the challenges, pitfalls, and best practices to advance our science from bench to bedside.

Navigating the possibilities in drug development

NAV-240 is a bispecific antibody with the potential for best-in-class efficacy. We believe NAV-240 has the potential to offer a new therapeutic option for people living with difficult-to-treat immune disorders.

Our Science
Indications
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

NAV-240

OX40L x TNFα bsAb

Indications

HS, RA, SSc

Phase 1

NAV-242

OX40L x TNFα bsAb
(2nd generation)

Indications

HS, RA, SSc

Preclinical

NAV-140

OX40L mAb

Indications

HS, RA, SSc

Preclinical

NAV-340

OX40L x Undisclosed bsAb

Indications

HS, RA, SSc

Discovery

bsAb = bispecific antibody, mAb = monoclonal antibody

Science-led.
Patient-inspired.

Autoimmune diseases are notoriously complex to treat. For some, the therapies don’t provide enough relief or work long enough between doses. For others, there are simply no viable options at all. These patients deserve better—and they inspire us every day to pursue modalities with the potential for safe, more effective treatments.